王峰博士：研究员、博士生导师； 中国科学院生物物理研究所国家级海外高层次人才；中国科学院百人计划（A类）学术帅才 ；生物大分子全国重点实验室药物方向负责人；科技部“合成生物学”重大专项首席科学家。

         苏州生物医药转化工程中心创始人、主任； 美国加州生物医药研究所创始成员、首席研究员。曾在美国加州生物医药研究所、斯克利普斯研究所和诺华制药集团长期从事生物医药研究工作，掌握生物大分子药物新靶点发现、药物筛选、开发的全过程，具有国际先进的新药研发、投资及项目运营管理经验。

         ​​​​多个创新项目授权给大型药企如辉瑞、默沙东、诺和诺德等进行产品开发。研究项目已获得了科技部重点研发计划、国家自然科学基金、中科院先导专项、药企、疾病基金会等经费支持，获得了全国颠覆性技术创新大赛优胜项目。

Feng Wang, PhD, Director, Suzhou Institute for Biomedical Research; Associate director and principal investigator at Key Laboratory of Protein and Peptide Therapeutics of Institute of Biophysics (IBP), Chinese Academy of Sciences (CAS). His research work focuses on developing new methods to identify and design novel antibody and antibody derivatives as therapeutics. Before joining IBP, Dr. Wang worked with Dr. Peter Schultz to establish California Institute for Biomedical Research (CaliBR) in 2012. He was principal investigator in charge of the group of protein therapeutics from 2012 to 2017. His work is currently supported by multiple state funding agencies and was funded by Bill & Melinda Gates Foundation, Juvenile Diabetes Research Foundation (JDRF), Pfizer and Merck & CO.  Dr. Wang got his Ph.D in biochemistry at TAMU and performed his postdoc research work at The Scripps Research Institute, La Jolla, California.

          张捷博士现任苏州生物医药转化工程中心常务副主任，拥有多年临床医学经验，于2000 年加入美国国际诺华制药集团，在诺华基因组研究所(GNF，美国加州圣地亚哥)工作的十三年里，参与了多项诺华全球新药研发项目。张捷博士是一位熟悉中国和欧美医药企业运营，具备企业战略规划制定和执行、医药创新和产业化等多方面能力的复合型人才。

Jay Zhang M.D./Ph.D, Deputy Director, Suzhou Institute for Biomedical Research, IBP, CAS; Dr. Zhang has over thirteen years’ experience in research and development at Novartis, with extensive experience in leading strategic planning & implementation process for biotech start-ups with strong global orientation.